BMS-986353 is an investigational CD19-targeted CAR T-cell product. The CD19-specific CAR consists of a single-chain variable fragment (scFv) binding domain derived from a CD19-specific monoclonal antibody (mAb; FMC63), an IgG-derived hinge region, a CD28 transmembrane domain, and the CD137 (41BB) and CD3? chain signaling domains. The third-generation SIN lentiviral vector, which encodes the CAR domains described above, also encodes a truncated human epidermal growth factor receptor (EGFRt) that is expressed separately from the CD19 CAR on the T cell surface
Diffuse-large B-cell Lymphoma (DLBCL)
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
271 Active assets in the Diffuse-large B-cell Lymphoma (DLBCL) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE National Cancer Institute (NCI) | Phase 2/3 | A |
Evomela Ruijin Hospital | Phase 4 | BBB |
Axicabtagene Ciloleucel Ruijin Hospital | Phase 4 | BBB |
PREDNISONE TABLETS Beth Israel Deaconess Medical Center | Phase 4 | BBB |
Inno-206 Beth Israel Deaconess Medical Center | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
BMS-986353 is an investigational CD19-targeted CAR T-cell product. The CD19-specific CAR consists of a single-chain variable fragment (scFv) binding domain derived from a CD19-specific monoclonal antibody (mAb; FMC63), an IgG-derived hinge region, a CD28 transmembrane domain, and the CD137 (41BB) and CD3? chain signaling domains. The third-generation SIN lentiviral vector, which encodes the CAR domains described above, also encodes a truncated human epidermal growth factor receptor (EGFRt) that is expressed separately from the CD19 CAR on the T cell surface is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →